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Abstract 
 
This research investigated the role that dietary fatty acids have in the detection of 
obesity-related diseases. While studies have focused on whether fatty acid 
composition changes due to various obesity-related diseases, e.g. Cardiovascular, 
metabolic syndrome, very few have investigated whether fatty acids can be used as 
biomarkers to detect the predilection towards obesity. In response this project 
investigated a range of animal and plant oils, as well as liver and adipose tissue 
samples to determine whether the composition of fatty acids is similar between a low 
fat diet and a high carbohydrate high fat diet, simulating the unhealthy diet eaten by 
many. Through the use of fatty acid methyl esters (FAME) which were derivitized 
using two different methods using either H2SO4 or BF3 as catalysts, samples were 
analysed by GC-MS. While both methods were viable, BF3 proved to be the more 
reliable method. Previous research completed by this laboratory was extended using 
tissue samples not previously examined. Results indicated that supplementation of 
the diet by EPA (C20:5) possibly attenuates the impact of obesity-related 
inflammation (p<0.05). Increased levels of n-3 PUFA in tissues from a diet 
supplemented with EPA indicates that preferential metabolism of anti-inflammatory 
eicosanoids may occur. The outcome of this research indicates that the composition 
of fatty acids produced by varying diets does differ and therefore may have an 
impact on obesity-related diseases. This research has contributed to current 
knowledge by extending previous findings (Poudyal et al., 2012b) from other tissues 
and provides further indication that study should continue in examining what role 
eicosanoids play in attenuating obesity-related diseases.  
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
 
Obesity poses one of the greatest challenges to public health in the 21st century with 
over 500 million adults afflicted (World Health Organisation, 2008) and is the 
Western world’s leading preventable cause of death. It can be defined as excess 
body fat that has accumulated to the extent that it may have a detrimental effect on 
health leading to a reduced life expectancy and/or increased health problems (World 
Health Organisation, 2008).  Obesity is caused by a positive energy balance (energy 
intake exceeding energy expenditure) which results in an expansion of adipose 
tissue stores and metabolism of fatty acids in cells which may have maladaptive 
responses to lipids (Poirier, 2007). Obesity has a significant impact on both the 
physical and psychological health of those who are affected as it leads to an 
increased risk of morbidity and mortality (Poirier, 2007). 
Obesity is associated with numerous metabolic disorders, such as dyslipidaemia, 
Type 2 diabetes and long term cardiovascular complications (Haslam and James, 
2005). Dietary fat and carbohydrates have both been implicated in obesity but on 
quality rather than quantity e.g. trans fatty acids (TFA) are created through the 
transformation of unsaturated fatty acids from their natural cis- form to the trans- 
form, and are abundant in the ‘western’ diet. They take on similar properties to 
saturated fatty acids (SFA) and appear to be more atherogenic and promote insulin 
resistance (Odegaard and Pereira, 2006). Saturated fatty acids and trans- fatty acids 
are generally accepted as being detrimetnal to health as studies have shown a 
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correlation between levels of these lipids and disease (Muoio, 2010, Quehenberger 
and Dennis, 2011). Both TFA and SFA have been found to be associated with 
systemic inflammation (Mozaffarian et al., 2004). 
Research has indicated that monounsaturated (MUFA) and polyunsaturated (PUFA) 
fatty acids found in dietary fat could possibly attenuate symptoms and risk factors of 
obesity in rats fed high carbohydrate, high fat diets (Poudyal and Brown, 2013). 
1.2 Fatty Acids 
 
Fatty acids are biomolecules that are present in all organisms and play a 
physiologically important role as building blocks in biomembranes, as signalling 
molecules and as energy storage.  Fatty acids are carboxylic acids with long 
aliphatic tails that are either saturated (no double bonds) or unsaturated (one or 
more double bonds). Naturally occurring fatty acids have straight chains of an even 
number of carbon atoms between 4 and 28 carbons in length. 
 A tissue’s fatty acid content is dependent on two major contributors. Firstly, fatty 
acids can be synthesised de novo through lipogenesis to produce short chain fatty 
acids (SCFA) (C2 to C6).  These SCFA are elongated through medium chain fatty 
acids (C8 to C12) to form palmitic acid (C16:0) and with further elongation to stearic 
acid (C18:0).  Enzymatic desaturation can add a double bond to produce palmitoleic 
(C16:1) and oleic (C18:1) acids respectively. Palmitic, stearic, palmitoleic and oleic 
acids can be derived from the diet as well. In mammals, essential fatty acids are not 
made in the body and must be derived from the diet. Linoleic acid (LA; C18:2) and α-
Linolenic acid (ALA) (C18:3) are the only two essential fatty acids. LA is elongated 
and desaturated to form dihomo-γ-linolenic acid (DGLA; C20:3), arachidonic acid 
(AA; C20:4) and docosapentaenoic acid (DPA; C24:5). ALA is elongated and 
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desaturated to form eicosapentaenoic acid (EPA; C20:5) through to 
docosahexaenoic acid (DHA; C20:5) (Poudyal and Brown, 2013). Arachidonic acid 
(C20:4) and EPA (C20:5) are the precursors of the eicosanoids, such as 
prostaglandins (PG), thromboxanes (TX) and leukotrienes (LT) and as such are 
physiologically and metabolically essential. 
Dietary fat sources are generally found to be the 18-carbon fatty acid series: linoleic 
(LA)(C18:2), α-linolenic (ALA) (C18:3), oleic (C18:1) and stearic (C18:0) (Poudyal et 
al., 2013) with the modern Western diet generally containing more linoleic rather 
than α-linolenic acid (Rett and Whelan, 2011). Excess fatty acids are stored as 
TAG’s in adipose tissue. Triacylglyerides have twice the energy per gram of 
carbohydrates and proteins.  
Fatty acids can either be beneficial or detrimental to the human body. Studies have 
found that n-3 (ALA, EPA, DHA) PUFA are beneficial, with anti-inflammatory 
properties through their conversion into eicosanoids (PG, TX, LT) while n-6 (LA, 
DGLA, AA, DPA) PUFA tend to elicit a pro-inflammatory response from their 
eicosanoids (Poudyal et al., 2013). The predominant n-6 PUFA is arachidonic acid 
(C20:4) which converts to series-2 PG, series-2 TX,  series-4 LT and other 
lipooxygenase and cyclooxygenase products (Arita et al., 2005, Serhan et al., 2007) 
which are regulators of cell function with inflammatory effects. EPA, the key 
intermediary n-3 PUFA, and DHA derived eicosanoids (series-3 PG, series-3 TX, 
series-5 LT, resolvins, docosatrienes and neuroprotectins) (Arita et al., 2005, Serhan 
et al., 2007) appear to antagonize the pro-inflammatory effects of n-6. 
Prostaglandins, Thromboxanes and Leukotrienes are assigned to either the 1,2,3,4, 
or 5 series based on the number of double bonds contained in the fatty acid.The n-3 
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eicosanoids down regulate inflammatory genes and lipid synthesis and stimulate 
fatty acid degradation (Schmitz and Ecker, 2008).  
The same series of desaturase and elongase enzymes are utilised by both n-3 and 
n-6 fatty acids in conversion to eicosanoids which leads to preferential metabolism 
towards the excess PUFA causing significant decreases in conversion of the other 
(Figure 1). Therefore, increase consumption of n-3 PUFA leads to reduced synthesis 
of inflammatory eicosanoids from n-6 arachidonic acid and elevated production of 
the anti-inflammatory n-3 converted eicosanoids. 
 
 
Figure 1. n-3 and n-6 fatty acid metabolism indicating the same series of desaturase and elongase enzymes 
needed for metabolism. Eicosanoids metabolised by arachidonic acid (n-6) or eicosapentaenoic acid (EPA) (n-3). 
(Schmitz and Ecker, 2008) 
 
Arachidonic Acid Pathway EPA Pathway 
(EPA) 
(DHA) 
(ALA) 
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Until recently, it had been thought that due to the similar chemical structures of fatty 
acids they would produce similar biological actions. Earlier studies from our 
laboratory investigating ALA, EPA and DHA and effects on rats fed a high-
carbohydrate, high-fat diet, found that the biological response to EPA and DHA were 
similar. ALA-rich supplementation increased the concentration of DHA in various 
tissues, indicating that ALA was also involved in the production of DHA (Poudyal et 
al., 2012b). The C18 unsaturated fatty acids have shown a tendency for partitioning 
lipids away from the abdomen (Poudyal et al., 2012b) suggesting that it is the 
proportion of these fatty acids in the dietary lipid pool and not just the diet that plays 
a significant role in response to long chain fatty acid synthesis (Poudyal et al., 
2012b). 
Abdominal and visceral fat have been linked to metabolic disturbances, and, an 
increased risk in cardiovascular disease and Type 2 diabetes. Therefore these fat 
deposits are more detrimental than peripheral fat storage (Rosito et al., 2008). 
Hence, PUFA and MUFA are beneficial as the decrease in visceral fat ameliorates 
the risk factors associated with obesity. EPA and DHA have been shown to cause a 
decrease in total body fat which will also attenuate the risk factors of insulin 
resistance, dyslipidaemia and hypertension (Poudyal et al., 2012a).   
 Arachidonic acid (C20:4) is a product of linoleic acid metabolism, and, as the key 
intermediate to  pro-inflammatory eicosanoids (TX, PG, LT), is a key regulator in 
inflammation (Poudyal et al., 2013). While too much arachidonic acid appears 
detrimental to health, it is proposed that the control mechanisms for fatty acid 
homeostasis shunt dietary arachidonic acid into specific metabolic pathways, such 
as the β-oxidation and the citric acid cycle ensuring utilization rather than  
accumulation in adipose tissue (Nelson et al., 1997). Recent research has found that 
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unchanged proportions of arachidonic acid in liver and skeletal muscle suggest that 
eicosapentanoic acid (EPA)  is preferentially metabolised over arachidonic acid to 
form anti-inflammatory and anti-hypertensive eicosanoids in these highly 
metabolically active adipose tissues (Poudyal et al., 2012b).  
Studies using genetically obese Zucker rats, which share several traits with obese 
humans, such as obesity and hyperinsulinaemia (Escoubet et al., 1987), and 
Sprague-Dawley rats (Zhang et al., 2009) have shown abnormal fatty acid 
composition in plasma tissues. Due to these similar traits rats are a useful alternative 
in studies on obesity.  
These rat models have shown higher linoleate intake increases arachidonic acid 
which in turn increases prostacyclin production, stimulating signalling pathways 
leading to adipogenesis (Ailhaud et al., 2008) . 
These pathways possibly include phospholipase and/or cyclo-oxygenase activation, 
and, may be linked to low n-3 PUFA intake as well as excessive dietary linoleate.  
(Ailhaud et al., 2008) also discussed the likelihood that excess dietary linoleate may 
play a role in adipose tissue development due to a demand for a higher intake of 
‘essential fatty acids’. This high n-6 PUFA intake and a very high ratio of n-6:n-3 
PUFA in the diet have also been implicated in the advancement of many obesity 
related diseases, including CVD, cancer, inflammatory and autoimmune diseases 
(Robinson et al., 2007). 
Human studies (Novgorodtseva et al., 2011)   have shown that disturbances in the 
composition of fatty acids within plasma, red blood cells and eicosanoid synthesis,  
play important roles in Metabolic Syndrome with decreased amounts of stearic acid 
(C18:0), arachidonic acid (C20:4), and docosapentaenoic acid (C22:5) seen, while 
the amount of linoleic acid (C18:2), the precursor of arachidonic acid (C20:4) was 
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doubled (Ailhaud et al., 2008, Escoubet et al., 1987, Novgorodtseva et al., 2011).  
There is also increasing evidence that obesity and Type 2 diabetes may be 
associated with a morphological defect in the mitochondria that leads to the inability 
of skeletal muscle to oxidise lipids, with the intracellular environment partitioning 
lipids towards storage instead (Consitt et al., 2009). Additional research is needed 
into the relationship between obesity and the accumulation of lipid intermediates and 
the impact that lipids have on insulin action (Consitt et al., 2009). 
1.3 Markers indicative of disease state 
1.3.1 Biomarkers  
Zhang et al. (2009) discussed the necessity of assessing the essential nutrient status 
of individuals to provide a more comprehensive systemic metabolic response to 
dietary, lifestyle and environmental influences. By increasing our understanding of 
the metabolic processes involved in the pathogenesis of obesity, a comprehensive 
understanding of the disease can be developed.  
Biomarkers are indicators of normal biological and pathogenic processes or 
responses to therapeutic interventions that can be objectively measured.  They are 
molecules found in blood or other body fluids or tissues that could be used as an 
indication of disease and could be used for routine screening tests, monitoring 
therapy or, prediction of therapeutic responses (Zhang et al., 2009).  Previous 
studies have used amino acids such as tyrosine and glutamine, proteins and 
cytokines (Cao et al., 2008, He et al., 2012, Kim et al., 2010), as biomarkers to 
identify molecules that discriminate healthy lean from healthy obese individuals. The 
analysis of fatty acid profiles in blood, plasma and tissue is becoming an important 
tool in clinical studies as an endpoint for detecting biomarkers of disease e.g. 
cardiovascular and other chronic diseases, and drug compliance (Masood and 
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Salem, 2008).  Previous research into obesity generally relied on subjective data, 
such as questionnaires. Difficulties in this form of research arise as fat intake is 
rarely observed directly and there can be a recall bias and measurement errors as 
well as changes in diet while filling out questionnaires (King et al., 2006). From this 
point of view a biological marker would be useful especially if it could be obtained 
using a blood sample which would provide a cheap, simple and a less time-
consuming process to determine fat intake.  With advancements in technology in the 
last three decades, detection of biomarkers with GC-MS has become a more time-
effective, less costly and less invasive way of measurement. A number of physio-
chemical properties of fatty acids, such as chain length, degrees of saturation and 
various other structural features could be used in the detection of biomarkers. For 
example, total fat, fatty acids, essential fatty acids, eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA) and eicosanoids could all potentially be utilised as 
biomarkers, and have already been identified as useful markers of cardiovascular 
disease (Masood and Salem, 2008).  
Studies have shown conflicting results when it comes to biomarkers representing 
total fat while red blood cell fatty acid concentrations of MUFA, PUFA and SFA do 
not appear to be adequate. EPA, DHA and oleic acid may provide short-term 
indicators of relative intake rather than total fat intake (Poppitt et al., 2005). 
Previously, trans-fatty acids were a good biomarker of dietary fatty acids, as they are 
generally not naturally found but have been manufactured during the processing of 
food. However, with the decreased prevalence in the diet they are becoming less 
helpful (Baylin et al., 2002). By comparing fatty acids, a biomarker profile may be 
created to indicate total fat intake. By using samples of red blood cells, plasma 
phospholipids and cholesterol esters, King et al. (2006) measured fatty acid status 
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and produced predictive models that were specific and sensitive in discriminating 
between low fat and high fat intakes.  
Studies by Baylin et al. (2002) Fuhrman et al. (2006), Thiébaut et al. (2009) 
examined biomarkers for relative fatty acid intakes and have produced outcomes 
where C18:2 and C18:3 showed strong correlations with dietary intake when 
measured in adipose tissue (Baylin et al., 2002). n-6 and n-3 PUFA in phospholipids 
have been noted to be long-term biomarkers of relative intake by Fuhrman et al. 
(2006). The study also reported that oleic acid (C18:1) in plasma and red blood cells 
is a valid long-term biomarker of total MUFA intake (Fuhrman et al., 2006). The red 
blood cell MUFA findings were corroborated by Thiébaut et al. (2009) while finding 
that red blood cell saturated fatty acids do not appear to be a suitable biomarker.  
EPA and DHA have been found to attenuate disease states in a number of studies 
(Masood and Salem, 2008, Poudyal et al., 2012b). They have been found to be 
antagonistic to C20:4, and, the eicosanoids that are subsequently produced by it.  In 
the past, EPA and DHA were obtained mainly through the consumption of fish. 
However, with the availability of EPA/DHA fortified foods and supplements due to the 
benefits of these fatty acids, the biomarker can indicate not only the dietary intake of 
fish but also EPA/DHA intake (Harris and von Schacky, 2004). Further research to 
determine the time-period of intake of plasma EPA and DHA may show that they are 
useful dietary biomarkers. Studies indicate that the Omega-3 Index, which is the sum 
of EPA and DHA in red blood cell membranes as a percentage of the total fatty acids, 
may also be a good biomarker of n-3 intake (Harris and von Schacky, 2004). 
Significant correlations between the Omega-3 Index, plasma phospholipid and whole 
blood EPA and DHA have been found (Harris and von Schacky, 2004). 
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The presence of these fatty acids in plasma can act as important biomarkers in 
cardiovascular disease risk (Masood and Salem, 2008) and other related diseases. 
However, it must be noted that some fatty acids are also endogenous e.g. palmitic 
acid (C16:0) and oleic acid (C18:1), and therefore show up in testing regardless of 
diet. It is likely that successful biomarkers of disease need to come from exogenous 
sources, such as LA (C18:2) and ALA (C18:3). Baylin et al. (2002) found high diet -
adipose tissue correlations for both of these acids. However, there was no 
correlation between dietary PUFA and adipose tissue C20:4. These findings suggest 
that there is little endogenous conversion of C18:2 to C20:4. Further research is 
needed to ascertain the usefulness of fatty acids as biomarkers. 
1.4 Methods of Analysis 
1.4.1 Transesterification methods    
With the nutritional and health benefits of fatty acids becoming evident, their analysis 
is of growing importance. Most fatty acids in biological samples are either 
triacylglycerols or phospholipids. The derivatization of fatty acids from biological 
samples are generally transesterifications (Carrapiso and Garcia, 2000). In order to 
analyse lipid samples, extraction is commonly done prior to esterification. Gas 
chromatographic analysis of fatty acids esters, such as methyl esters (FAME), rather 
than of the free fatty acids, is the preferred method as their analysis is more accurate 
and selective. FAME are prepared more often than other esters due to their greater 
volatility, therefore improving peak shape and resolution of the more common fatty 
acids (C14:0 – C22:0) (Carrapiso and Garcia, 2000).  
The most commonly used lipid extraction method is the Folch method (Folch et al., 
1957). This rapid and simple method of extraction is similar to the Bligh and Dyer 
(1959) method (Bligh and Dyer, 1959). Many current methods are based on these 
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two methods, as they both require the same solvents (chloroform and methanol) and, 
similar procedures. Both methods are efficient, easily reproduced and safe to 
perform.  
Transesterification is a catalysed substitution reaction where TAGs are reacted with 
an alcohol (e.g. methanol, ethanol) to form glycerol and three equivalents of FAME. 
In the acid catalysed reaction, the carbonyl carbon and oxygen from the methanol 
hydroxyl group interact. As this bond is formed, electroneutrality is restored by 
deprotonation. Cleavage of the glycerol group and subsequent protonation gives the 
three FAME’s and glycerol products. The same products are generated when BF3 is 
used as the catalyst. 
  
Figure 2. Transesterification reaction with methanol and a sulphuric acid (H2SO4) catalyst. 
(Diagram: ww2.mackblackwell.org)  
 
A number of studies have utilised a similar approach to the current study being 
undertaken using a combination of sulphuric acid (H2SO4) and methanol to 
transesterify lipids (Antolin et al., 2008, Wei and Zeng, 2011). Methods utilising 
boron trifluoride (BF3) are also used in lipid derivatization (Araujo et al., 2008, Park 
et al., 2010). The current study will attempt to validate the results of adipose 
H2SO4 
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tissue/liver samples previously transesterified under a BF3 method (Poudyal et al., 
2012b) by comparison with a H2SO4/methanol procedure. 
  
1.4.2 Analysis methods 
There are two major high throughput tools that are used in metabolomics to identify 
metabolites – Nuclear Magnetic Resonance (NMR) spectroscopy and Mass 
Spectrometry (MS).  MS is the most frequently used method as it has a high level of 
sensitivity and is a powerful tool not only to detect and quantify metabolites but also 
to investigate the molecular structure (Zhang et al., 2012).  When combined with gas 
chromatography (GC) distinct metabolite classes can be detected reducing the 
complexity of the mass spectra. 
Due to the complexity of the human metabolome, a multi-platform approach to 
analysis provides a more comprehensive understanding of alterations to metabolism. 
Combining approaches allows for complementary analytical outcomes, which can 
broaden the metabolic variations identified (Zhang et al., 2012).  A study undertaken 
by Williams et al. (2006) investigated the metabolic regulatory mechanisms present 
in diabetes. The metabolic profile was obtained from normal Wistar-derived (n=5) 
and Zucker (fa/fa) (n=6) obese rats using multiple analytical platforms, including 
NMR, UPLC-MS and GC-MS. The study was able to detect differences in the profiles 
of the two strains of rats. For example, a number of biomarkers including cholesterol, 
arachidonic acid (C20:4), oleic acid (C18:1), palmitic acid (C16:0), 
monooleoylglycerol and low density and very low density lipoproteins were found to 
be higher in the Zucker variety. A follow up study using only Zucker rats (n=18) 
detected over 200 compounds in each plasma sample. It found that lean (n=6) and 
lean/fa (n=6) genotypes had similar compounds while the fa/fa (n=6) genotype was 
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distinct from the others. Evidence obtained from GC-MS analysis, indicated that 
differences in plasma were due to disease states rather than the strain of rat, when 
related to the previous Wistar –Zucker rat study (Major et al., 2006).  
Both of the studies’ samples were analysed using the same conditions.  The 
samples were analysed using NMR, GC-MS and UPLC techniques (Major et al., 
2006, Williams et al., 2006). By performing two complementary studies using the 
same conditions and evidence correlated between both studies it showed that the 
GC-MS is a valuable tool that is reliable and robust in performing research. Also, by 
using similar samples with different techniques they were able to distinguish overlaps 
in metabolites between the GC-MS and NMR but not with the UPLC (Major et al., 
2006, Williams et al., 2006). This indicates that by using a multiplatform analytical 
study a wider range of unique markers can be identified.  
While most methods using GC-MS have analysis times of over 30 minutes (Araujo et 
al., 2008, Baylin et al., 2002), Ecker et al. (2012) developed a rapid method for 
quantification of positional and geometric isomers of FAMEs using a highly polar 
column (10m x 0.10mm, 0.20μm) which runs for 17.2 minutes. This method has 
been shown to be robust and reliable for routine analysis of plasma and tissue 
extractions and has been used in various studies (Ecker et al., 2010a, Ecker et al., 
2010b). Fast, reliable methods are useful in processing large numbers of samples 
with a relatively quick turnaround.  
 
1.5 Conclusion 
Obesity is a worldwide public health issue with numerous risk factors and co-
morbidities. It appears that fatty acids play a role in the development of many of 
these disease states, but the how and why are still to be elucidated. Research has 
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shown that dietary supplementation with fatty acids, particularly n-3 PUFA can 
attenuate some of the negative impacts of obesity but how they work is still not well 
understood. Currently there are few studies addressing the differences in 
metabolism between healthy and obese individuals. This study will describe how 
fatty acids could be suitable biomarkers of the pathophysiology of obesity. The study 
will utilise liver, and adipose tissue samples from rats fed a high-carbohydrate, high-
fat diet by the Brown Research Group at USQ. 
1.6 Research Project 
1.6.1 Research Hypothesis 
 
That fatty acid composition of the liver and adipose (retroperitoneal fat) tissue is 
altered by a diet that is high in carbohydrates and fats, and, these differences can be 
quantified. 
 
 
1.6.2 Research Objectives 
The object of this project is to investigate whether the fatty acid composition of liver 
and adipose (retroperitoneal fat) tissue in rats is altered dependant on the diet that 
they are fed.  Results from previous research (Poudyal et al., 2012b)  will be 
validated by using an alternative method of derivitization.  
 
The objectives of this project are: 
• Establish a methodology for the analysis of fatty acids by comparing results 
from BF3 method to H2SO4 method. 
• Extend previous research by analysing liver and adipose tissue samples 
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• Evaluate if fatty acid composition is altered based on the diet fed to rats on 
the HCHF rat model of obesity 
• Determine if dietary supplementation with EPA alters fatty acid composition. 
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CHAPTER 2 
EXPERIMENTAL PROCEDURES 
 
2.1 Chemical Preparations 
 
Chloroform, methanol, heptadecanoic acid (C17), sodium hydroxide, 2-propanol, 
sodium chloride and 14% boron trifluoride in methanol were obtained from Sigma-
Aldrich. HPLC grade methanol was obtained from Lab Scan Analytical Sciences. 
Concentrated sulphuric acid (H2SO4) was obtained from Proanalys. Milli-Q high 
purity water was used. All other reagents and solvents were of analytical grade or 
better and were used with no further purification, unless otherwise noted. 
Two multi-acid standard mixtures were used to check performance of the gas 
chromatograph/mass spectrometer :Fatty Acid Methyl Ester Mix (C14:0 to C22:0) 
was obtained from Sigma Aldrich and for identification purposes: GLC-462 
Reference Standard, containing a mixture of 28 fatty acid methyl esters obtained 
from Nu-check Prep Inc. 
Oils that were used in the large scale H2SO4 method development included plant 
oils (chia, flax, olive, avocado, macadamia, canola and safflower) and animal oils 
(beef tallow, EPA and DHA). These were kindly supplied by Dr. Hemant Poudyal.  
2.2 Chromatographic conditions 
 
Fatty acid methyl esters were identified using gas-chromatography-mass 
spectrometry. A Shimadzu GC-2010 gas chromatograph with an AOC-20i 
autoinjector sampled from an AOC-20s autosampler using an RTX-5MS capillary 
column (30m x 0.25mm x0.25µm) (serial number 801339). A Shimadzu GCMS-
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QP2010 Plus mass spectrometer detector using an electron ionisation ion source 
was used to produce the mass spectra. 
Oven conditions for this method were developed using a standard of FAMEs (C14:0 
to C22:0) (Sigma Aldrich) and esterified C17.  An initial oven temperature of 150°C 
was held for 5 minutes, the temperature was increased to 180°C at a rate of 
19°C.min-1. Upon reaching 180°C the oven was held at this temperature for 16 
minutes. The temperature was increased to 200°C at a rate of 8°C.min-1 and held for 
a further 5 minutes, then increased again to 240°C at 8°C.min-1 and held for a further 
20 minutes.  The method required a total run time of 55.08 minutes. 
A volume of 1.0 µL was injected for each sample with an injection temperature of 
250°C utilising a 10:1 split ratio using ultra-pure helium carrier gas at a linear velocity 
of 25.0 cm.s-1 at a pressure of 26.1 kPa. The column flow rate was 0.43 mL.min-1. A 
purge flow of 3.0 mL.min-1 was used, with a total flow rate of 7.8 mL.min-1. 
The mass spectrometer conditions used an ion source temperature of 285°C and 
interface temperature of 250°C with a MS scan mode of 40 - 400 m/z with an initial 
solvent cut time of 4 minutes. Events were measured every 0.5 seconds at a scan 
speed of 759 amu/sec.  
2.3 Preparation of Tissue samples 
 
Liver and adipose (retroperitoneal fat) tissue samples were kindly supplied by Dr 
Hemant Poudyal and were collected as part of studies described previously (Poudyal 
et al., 2012b) . 
Experiments for this project were conducted on liver and adipose (retroperitoneal fat) 
tissue samples. For each method (H2SO4 and BF3)  samples were prepared with 
corn starch diet (CS) (n=3) as the healthy control, high carbohydrate high fat (HCHF) 
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(n=3) as the unhealthy control, CS with EPA supplementation (CEPA) (n=3) and 
HCHF with EPA supplementation (HEPA) (n=3) as the treatment groups.  
Using forceps and scissors approximately 1 – 5 g of tissue was cut from the sample 
and added to a pre-weighed 15 mL polypropylene centrifuge tube. Tubes were then 
re-weighed and the mass of the sample accurately determined.  
 
2.4 Lipid Extraction 
 
The extraction of lipids from liver and adipose tissue samples was undertaken using 
a manual solvent extraction method using a 2:1 chloroform/methanol mixture.  
To a tissue sample prepared as above, 10 mL of chloroform/methanol solvent was 
added. With the cap firmly on this was mixed on a mechanical shaker for 30 minutes.  
The sample was then centrifuged at 4000 rpm for 5 minutes. The solvent (lower layer) 
was aspirated from the tube and placed into a 50 mL polypropylene centrifuge tube. 
This extraction process was repeated a further two times and all of the extracted 
solvent was combined.  
5 mL of 5% NaCl solution was added to the chloroform extract and the mixture was 
centrifuged at 4000 rpm for 5 minutes to separate the different phases. The aqueous 
phase was removed and discarded. The sample was mechanically shaken for a 
further 30 minutes and centrifuged for 5 minutes at 4000 rpm. Any remaining water 
was removed.  
Samples were transferred to pre-weighed glass vials and the solvent was 
evaporated under a gentle stream of compressed air on a hot plate set at 50°C. 
Dried samples were stored under nitrogen for future fatty acid analysis.  
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2.5 Transesterfication using H2SO4 Method 
2.5.1 Bulk Oils 
This method was developed using a variety of plant oils (chia, safflower, canola, 
macadamia, olive, avocado and flax) and animal oils (beef tallow, EPA and DHA).  
The procedure for transesterfication was a modified version of that detailed in Folch 
et al. (1957). A sample of 1.0 g of oil was combined with 25 mL methanol and 1 mL 
of H2SO4 in a round bottomed flask with a magnetic stirrer. This was placed in a 
glycerol bath, ensuring the liquid was 2 - 3 mm below the level of the glycerol. The 
mixture was heated at reflux for two hours.  After two hours, heating was 
discontinued, the flask was removed from the glycerol and allowed to cool. 
To the mixture 25 mL water was added and this was transferred to a 250 mL 
separatory funnel.  The mixture was extracted with 20 – 30 mL of diethyl ether.  The 
ether layer was collected and the aqueous phase was further extracted with 20 – 30 
mL of diethyl ether. This process was repeated. The combined ether extracts were 
washed three times with portions of 20 – 30 mL of water.  
The diethyl ether extract was transferred to a clean beaker. Excess ether was 
evaporated off under a stream of compressed air. Prior to total evaporation samples 
were transferred to glass storage vials where evaporation was completed. Samples 
were re-suspended with HPLC grade methanol for analysis by GC-MS. 
2.5.2 Lipids Derived from Tissue Samples 
 
Samples collected from lipid extraction were transesterfied to produce fatty acid 
methyl esters (FAME). The procedure for transesterfication was a modified version 
of that conducted at large scale (see section 2.5.1).  
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Sulphuric Acid Method 
To 0.02 g of the lipid extracts 5.5 mL methanol, 0.5 mL of H2SO4 and a few anti-
bumping granules were added. The test tubes were placed in a bath of glycerol and 
heated at 65°C for two hours.  After two hours, the heating was discontinued, the 
tubes were lifted out of the glycerol and allowed to cool. 
A volume of 6 mL water was added to the sample and the mixture was transferred to 
a 50 mL separatory funnel.  Samples were extracted with 10 mL of ether for 30 
seconds with the pressure released periodically.  The aqueous phase was removed 
and the ether layer collected. The aqueous phase was extracted with further 10 mL 
portions of ether twice more.  The combined ether extracts were washed three times 
with 10 mL portions of water. The ether phase was transferred to a glass vial and the 
ether was evaporated under a stream of compressed air. Samples were re-
suspended with HPLC grade methanol for GC-MS analysis. 
2.6 Transesterfication using BF3 Method 
2.6.1 Internal standard solution 
A mass of 100 mg of heptadecanoic acid (C17) was dissolved in isopropanol and 
was made up to 10.0 mL in a volumetric flask.  
2.6.2 Reagent preparation 
Reagents prepared for use were 0.5 M methanolic NaOH. This was prepared fresh 
prior to each set of experiments, by dissolving 1 g of NaOH in 50 mL CH3OH. Boron 
Trifluoride-Methanol (BF3-CH3OH) 14% was used as supplied by Sigma Aldrich.  
NaCl was saturated by dissolving 500 g in 500 mL of water.  
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2.6.3 Transesterification of extracted fatty materials 
All 12 HEPA and CEPA liver and retroperitoneal fat samples were prepared at once 
and transesterified together. 
All 12 control HCHF and CS liver and retroperitoneal fat tissue samples were 
prepared and transesterified at the same time.  
About 15 - 30 mg of prepared sample was placed in a test tube with 100 μL of the 
internal standard solution and  0.5 mL of 0.5 M methanolic NaOH. The tube was then 
flushed with N2 and a vented stopper was placed loosely in the top.  
Test tubes were heated in a 95°C water bath for 3 - 5 minutes to saponify the fats. 
Tubes were cooled and then 2.5 mL BF3-methanol was added using a syringe 
through the vented stopper. Tubes were then placed in the water bath for 5 minutes 
to esterify the fatty acids before being cooled to room temperature.  Heptane (2.0 mL) 
was added with a syringe.  The tubes were mixed using a vortex mixer. A volume of 
5 mL of saturated NaCl was added and the tubes were again mixed.   
Once the phases had separated, the heptane phase was collected and placed in a 2 
mL autosampler vial with a clean Pasteur pipette. The tubes were capped and were 
subsequently analysed by GC-MS. 
2.6.4 Calibration Standard 
For calibration with the C17 internal standard, three working standards were 
prepared with 50, 100 and 150 µL of the C17 internal standard present in each test 
tube (Figure 3). 
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Figure 3. Concentration vs. Peak Area of C17 Standard. 
 
2.6.5 Method validation 
For method validation purposes four blinded standards of saturated fatty acids 
(Lauric, Myristic, Palmitic and Stearic) were prepared by Dr Hemant Poudyal as per 
the BF3 derivitization method previously described, these were analysed using the 
same GC-MS program for quality control purposes.  
 
2.7 Statistical Analysis 
All data are presented as mean±SEM. Data from animal oil, plant oil, liver and 
adipose tissue samples were tested by one way analysis of variance (ANOVA). 
When interaction and/or main effects were significant, means were compared using 
Newman-Keuls multiple comparison post hoc test. A P value of <0.05 was 
considered as statistically significant. All statistical analyses were performed using 
GraphPad Prism version 6.0 for Windows (San Diego, CA, USA).  
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CHAPTER 3 
RESULTS 
3.1 Method Validation 
 
Table 1 and Figures 4-7 present the validation results of the four blinded standards. 
Each of the samples are indicated in Table 2 with above 80% purity, except sample 
2 which is at 69.56%.The retention times of the samples are indicated in Figures 3-7. 
Sample 1 has a retention time of 7.368 which correlates to lauric acid (C12:0), 
sample 2 at 11.348 is myristic acid (C14:0), sample 3 or palmitic acid (C16:0) at 
18.479 and sample 4 at 28.974 correlates with stearic acid (C18:0). The internal 
standard of C17 has a retention time of 24.066 (Table 2). 
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Table 1. Fatty acid profile of blinded standards used as method validation.  
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row with unlike superscript are significantly different. P <0.05.   No 
superscript within a row indicates no significant difference between groups.
Fatty Acid 
(g/100 of total) 
Sample 1 
(n=3) 
Sample 2 
(n=3) 
Sample 3 
(n=3) 
Sample 4 
(n=3) 
C10:0 
2.25±1.12 0.00±0.00 0.00±0.00 0.00±0.00 
C12:0 
86.00±10.63b 0.00±0.00a 4.38±4.38a 0.00±0.00a 
C12:1 11.75±11.75 0.00±0.00 0.45±0.45 0.00±0.00 
C14:0 
0.00±0.00b 69.56±1.51a 6.98±3.49b 0.00±0.00b 
C14:1n-5 
0.00±0.00b 30.44±1.51a 0.00±0.00b 0.00±0.00b 
C16:0 
0.00±0.00b 0.00±0.00b 88.20±1.34a 1.08±1.08b 
C18:0 0.00±0.00b 0.00±0.00b 0.00±0.00b 80.95±7.90a 
C18:2n-6 0.00±0.00 0.00±0.00 0.00±0.00 15.14±7.57 
C18:3n-3 0.00±0.00 0.00±0.00 0.00±0.00 2.83±1.41 
Total Saturated 88.25±11.75 69.56±1.51 99.55±0.45 82.03±8.98 
Total Unsaturated 11.75±11.75 30.44±1.51 0.45±0.45 17.97±8.98 
Total Monounsaturated 11.75±11.75 30.44±1.51 0.45±0.45 0.00±0.00 
Total Polyunsaturated 0.00±0.00 0.00±0.00 0.00±0.00 17.97±8.98 
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Figure 4. Chromatogram indicating retention time for sample 1. 
 
 
Figure 5. Chromatogram indicating retention time for sample 2. 
 
Figure 6. Chromatogram indicating retention time for sample 3. 
Retention Time (min) 
Retention Time (min) 
Retention Time (min) 
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Figure 7. Chromatogram indicating retention time for sample 4. 
 
 
Table 2. Retention Time of Saturated Fatty Acid Samples and C17 Standard. 
Fatty Acid Retention Time (min) 
C12:0 7.368 
C14:0 11.348 
C16:0 18.479 
C17:0 24.066 
C18:0 28.974 
 
Oven conditions for the GC-MS analysis were developed using a standard of FAMEs 
(C14:0 to C22:0) (Sigma Aldrich) and esterified C17 (Figures 8 and 9). 
 
Retention Time (min) 
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Figure 8. Chromatogram and retention time of FAME standard mix. 
 
 
 
 
 
 
Figure 9. Chromatogram and retention time of esterified C17 and adipose tissue.
Peak No Peak name Ret. Time. (min) Area Area % 
1 C14:0 21.340 20572069 3.86 
2 C16:0 30.639 55277415 10.38 
3 C18:2 38.239 173835459 32.66 
4 C18:1 38.571 172108330 10.28 
5 C18:1cis-9 38.831 54700119 32.33 
6 C18:0 39.761 34520835 6.48 
7 C20:0 51.005 10588956 1.99 
8 C22:0 60.617 10746239 2.02 
Peak No Peak name Ret. Time. (min) Area Area % 
1 BHT 7.505 595150 1.58 
2 C16:0 18.455 2492701 6.61 
3 C17:0 24.198 1265193 3.36 
4 C18:2 27.096 6726191 17.84 
5 C18:3 27.428 25250010 66.95 
6 C18:1 27.642 168138 0.45 
7 C18:0 28.604 1210405 3.21 
Retention Time (min) 
Retention Time (min) 
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The retention time of C10:0 to C24:1 indicates that the fatty acids were eluting from the column in order of chain length. However, the 
unsaturated fatty acids were eluting from the column earlier than the saturated fatty acids as indicated on Figure 10 and Table 3. For example, 
the C18 series of fatty acids has the order of C18:3 (RT = 26.221), C18:2 (RT= 26.925), C18:1n-9 (RT=27.277), C18:1n-7 (RT = 27.497) and 
C18:0 (RT=28.447). 
 
Figure 10. Chromatogram indicating retention time of fatty acid standards (C10:0 to C24:0).
Retention Time (min) 
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Table 3. Retention time of Standard fatty acids (C10:0 to C24:0). 
Fatty Acid Retention Time 
(min) 
C10:0 4.712 
C12:1 7.305 
C12:0 7.404 
C14:1 10.88 
C14:0 11.138 
C16:1 17.27 
C16:0 18.249 
C18:3 26.221 
C18:2 26.925 
C18:1 27.277 
C18:1 27.497 
C18:0  28.447 
C20:4 33.68 
C20:5 33.877 
C20:3 34.176 
C20:2 34.65 
C20:1 34.811 
?? 34.854 
C20:0 35.371 
C22:6 38.399 
?? 38.573 
?? 38.796 
?? 39.66 
C22:1 39.783 
?? 39.909 
C22:0 40.525 
C24:1 47.018 
C24:0 48.159 
?? Indicate unidentified fatty acids. 
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3.2 Analysis of Dietary Components 
 
Various dietary components from both plant and animal sources were analysed to 
determine their fatty acid profiles (p<0.05). Samples from rat liver and adipose 
(retroperitoneal fat) tissues were then investigated to identify the fatty acid profiles as 
a comparison to the fatty acids profiles (p<0.05)  of the diet that the animals were fed.  
3.2.1 Analysis of Plant Oils 
 
The fatty acid profiles of the various plant oils that are consumed as dietary components 
indicate that there is a high percentage of unsaturated fatty acids in macadamia 
(97.50±0.02), canola (94.28±0.09) and chia (93.52±2.80) while safflower (73.69±3.22) has 
the lowest amount (Table 4).  Safflower has the highest amount of saturated fatty acid with 
26.31±3.22 while macadamia has the lowest levels with 2.50±0.02 (Table 4). 
There are higher levels of C16:0 in olive (15.16±2.48) and avocado (15.22±0.01) compared 
to the other samples, while C16:1 are higher in the avocado (5.68±0.36), chia (2.67±2.67) 
and macadamia (4.15±0.01) samples (Table 4). There is no C16:1 in safflower, flax and 
canola and only a minimal amount (0.14±0.14) in olive oil (Table 4).  
In the C18 series, safflower (18.02±4.09) has the highest proportion of C18:0 while avocado 
has none (Table 4). Chia (90.58±2.58), flax (89.11±0.59) and safflower (73.11±3.19) have 
high polyunsaturated (C18:2; C18:3) fatty acids while macadamia (91.17±0.01), canola 
(76.97±1.33), avocado (76.35±0.01) and olive (75.48±1.07) are highest in monounsaturated 
(C18:1) fatty acids with flax having no monounsaturated fatty acids and chia (2.94±2.73) 
and safflower (0.58±0.04) only having low levels (Table 4). Safflower (73.11±3.19) consists 
mainly of C18:2, while macadamia (2.62±0.12) has the lowest level. C18:2 is the fatty acid 
that varies the most across the various samples (Table 4). Chia and flax have high levels of 
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C18:3 (69.16±2.00 and73.30±0.45 respectively), while there is none present in safflower, 
olive, avocado and canola, with only a minimal amount (3.70±0.15) found in macadamia 
(Table 4).There was only low levels of C20:4 found in canola (0.62±0.01) and chia 
(0.08±0.08) with none in the other samples (Table 4). 
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Table 4. Fatty acid composition of various plant oils used as dietary components. 
 
 
 
 
 
 
 
 
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row with unlike superscript are significantly different. P <0.05. No 
superscript indicates no significant difference between groups. 
Fatty Acid 
(g/100 of total) 
 
CHIA 
(n=3) 
 
SAFFLOWER 
(n=3) 
 
FLAX 
(n=3) 
 
OLIVE 
(n=3) 
 
MACADAMIA 
(n=3) 
 
AVOCADO 
(n=3) 
 
CANOLA 
(n=3) 
C16:0 2.89±2.89
b 8.29±1.45b 4.93±0.64b 15.16±2.48a 1.88±0.01b 15.22±0.01a 4.06±0.06b 
C16:1n-7 2.67±2.67
ab 0.00±0.00a 0.00±0.00a 0.14±0.14a 4.15±0.01ac 5.68±0.36bc 0.00±0.00a 
C18:0 3.59±0.13
a 18.02±4.09b 5.97±0.58a 0.61±0.61a 0.62±0.02a 0.00±0.00a 1.66±0.03a 
C18:1n-9 0.27±0.13
e 0.58±0.04e 0.00±0.00e 75.34±1.89c 87.02±0.01a 70.68±0.36d 76.97±1.33b 
C18:2n-6 21.34±0.55
b 73.11±3.19a 15.81±0.58c 8.75±1.54d 2.62±0.12e 8.42±0.01d 16.69±1.43c 
C18:3n-3 69.16±2.00
b 0.00±0.00d 73.30±0.45a 0.00±0.00d 3.70±0.15c 0.00±0.00d 0.00±0.00d 
C20:4n-6 0.08±0.08
b 0.00±0.00b 0.00±0.00b 0.00±0.00b 0.00±0.00b 0.00±0.00b 0.62±0.01a 
Total Saturated 6.48±2.80
be 26.31±3.22d 10.89±0.59ce 15.77±2.38ac 2.50±0.02b 15.22±0.01ce 5.72±0.09bc 
Total Unsaturated 93.52±2.80
ae 73.69±3.22d 89.11±0.59ce 84.23±2.38bc 97.50±0.02a 84.78±0.01bc 94.28±0.09ac 
Total Monounsaturated 2.94±2.73
c 0.58±0.04c 0.00±0.00c 75.48±1.07b 91.17±0.01a 76.35±0.01b 76.97±1.33b 
Total Polyunsaturated 90.58±2.58
a 73.11±3.19b 89.11±0.59a 8.75±1.54d 6.33±0.03d 8.42±0.01d 17.31±1.42c 
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 3.2.2 Analysis of Animal Oils 
 
The profiles of the animal oils tested indicate that beef tallow consists of a high 
percentage (64.84±0.68) of saturated fatty acids (C14:0 – 4.62±0.08; C16:0 - 
32.24±0.31; C18:0 – 27.98±0.28) with lower levels of unsaturated fatty acids, mainly 
monounsaturated C18:1 (32.23±0.31) and a small amount of polyunsaturated C18:2 
(1.11±0.02) (Table 5). EPA and DHA samples are 100% polyunsaturated fatty acids. 
EPA (91.86±1.49) consists mainly of C20:5 and DHA (90.26±0.25) of C22:6 which is 
consistent with their chemical nature (Table 5). The composition of EPA (2.73±0.66) 
and DHA (3.90±2.39) indicate that low levels of C20:4 are present. DHA (5.84±2.50) 
also contains C20:5 (Table 5).  
Table 5. Fatty acid composition of Animal oils. 
Fatty Acid 
 (g/100 of total) 
 
BEEF TALLOW 
(n=3) 
 
EPA 
(n=3) 
 
DHA 
(n=3) 
C14:0 4.62±0.08 0.00±0.00a 0.00±0.00a 
C16:0 32.24±0.31 0.00±0.00a 0.00±0.00a 
C16:1n-7 1.36±0.01 0.00±0.00a 0.00±0.00a 
C18:0 27.98±0.28 0.00±0.00a 0.00±0.00 
C18:1n-9 32.23±0.31 0.00±0.00a 0.00±0.00a 
C18:2n-6 1.11±0.02 0.00±0.00a 0.00±0.00a 
C20:4n-6 0.00±0.00 2.73±0.66 3.90±2.39 
C20:5n-3 0.00±0.00a 91.86±1.49b 5.84±2.50c 
C22:6n-3 0.00±0.00a 5.41±0.83b 90.26±0.25c 
Total Saturated 64.84±0.68 0.00±0.00a 0.00±0.00a 
Total Unsaturated 35.16±0.68 100.00±0.00a 100.00±0.00a 
Total 
Monounsaturated 
34.04±0.66 0.00±0.00a 0.00±0.00a 
Total Polyunsaturated 1.11±0.02 100.00±0.00a 100.00±0.00a 
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row with unlike superscript are 
significantly different. P <0.05.  No superscript indicates no significant difference between groups.  
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3.3 Analysis of Tissue Samples 
 
3.3.1 Analysis of Liver samples  
 
Fatty acid profiles of liver from rats fed with corn-starch (CS) or high carbohydrate 
high fat (HCHF) diets and with EPA supplementation (CEPA and HEPA) were 
analysed using differing methods of derivitization. Each group was compared against 
each other group. 
The H2SO4 method indicates a number of differences (p<0.05): Palmitoleic acid 
(C16:1n-7) in CS (2.60±0.01) treatment is higher than in the HCHF (0.35±0.35) 
samples (p<0.05) with none in the CEPA and HEPA samples, stearic acid (C18:0) in 
the HCHF (8.56±1.75) is lower than in the HEPA fed groups (32.34±8.34) (p<0.05) 
while it is also different between the CS (14.16±0.47) and HCHF (p<0.05) (Table 6). 
Oleic acid (C18:1n-9) in the HCHF (55.54±2.90) group is higher than in the CS 
(33.18±2.0), CEPA (24.08±2.13) and HEPA (15.86±8.29) groups (p<0.05) (Table 6). 
The total monounsaturated fatty acid composition of the CS fed group (39.87±2.95) 
differs from the HEPA group (16.98±8.87)(p<0.05) (Table 6). In the HCHF group 
(57.58±4.14) the monounsaturated fatty acid composition is higher than to the CS 
(39.87±2.95), CEPA (24.67±2.94) and HEPA (16.98±8.87) groups (p<0.05) (Table 6). 
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Table 6. Liver fatty acid composition in groups fed CS, HCHF, CEPA and HEPA diets using H2SO4 
derivitization method. 
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row with unlike 
superscript are significantly different. P <0.05. No superscript within a row indicates no significant difference between groups. 
 
 
Using the BF3 derivatization method DHA differs between CS (3.94±1.55) and HCHF 
(4.01±0.96) as well as HCHF (4.01±0.96) and HEPA (6.53±0.10) (Table 7). Total 
polyunsaturated fatty acids are also differing between CS (20.21±4.90) and CEPA 
(15.30±1.22) as well as HCHF (14.84±2.29) and HEPA (27.41±0.87) (Table 7). Low 
levels of Dihomo-γ-linolenic acid (C20:3n-6) were found in CS (0.28±0.28) and HEPA 
(0.36±0.36) with none in HCHF or CEPA (Table 7).  
 
 
 
 
 
Fatty Acid 
(g/100 of total) 
 
CS 
(n=3) 
 
HCHF 
(n=3) 
 
CEPA 
(n=3) 
 
HEPA 
(n=3) 
C14:0 0.49±0.49 0.99±0.50 0.00±0.00 0.00±0.00 
C16:0 31.38±0.97 27.09±3.90 38.27±5.80 38.64±7.10 
C16:1n-7 2.60±0.01 0.35±0.35a 0.00±0.00a 0.00±0.00a 
C18:0 14.16±0.47ab 8.56±1.75b 25.71±2.92ab 32.34±8.34a 
C18:1n-9 33.18±2.50b 55.54±2.90a 24.08±2.13b 15.86±8.29b 
C18:2n-6 4.21±1.23 2.70±0.05 5.08±2.66 5.08±2.55 
C20:4n-6 8.57±1.54 1.89±0.95 3.22±1.74 4.69±2.40 
C22:6n-3 1.37±0.70 2.09±1.33 3.05±1.55 2.27±2.27 
Total Saturated 45.98±0.82 36.64±5.02 63.97±8.70 70.98±15.44 
Total Unsaturated 54.02±0.82 63.36±5.02 36.03±8.70 29.02±15.43 
Total 
Monounsaturated 
39.87±2.95b 57.58±4.14a 24.67±2.94bc 16.98±8.87c 
Total 
Polyunsaturated 
14.15±3.39 5.78±0.88 11.36±5.92 12.04±6.60 
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Table 7. Liver fatty acid composition in groups fed CS, HCHF, CEPA and HEPA diets using BF3 derivatization 
method. 
 
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row with unlike 
superscript are significantly different. P <0.05. No superscript within a row indicates no significant difference between groups. 
 
3.3.2 Analysis of Adipose (retroperitoneal fat) Samples 
 
Tables 8 and 9 show the fatty acid profile of adipose (retroperitoneal fat) tissue from 
rats fed a corn-starch (CS) or high carbohydrate high fat (HCHF) diets and with EPA 
supplementation (CEPA and HEPA) using differing methods of derivitization. Each 
group was compared to each other group.  
Using the H2SO4 method, palmitic acid (C16:0) is lower in the CEPA samples 
(25.94±10.92) than HCHF (59.31±1.13), HEPA (58.12±0.85) and CS (46.52±1.46) 
(Table 9). Arachidonic acid (C20:4n-6) is found in low levels in CEPA (3.87±3.87) 
and HCHF (0.18±0.18) but not in CS or HEPA (Table 9). Total saturated fatty acids 
are highest in the CEPA fed samples (47.74±1.28), followed by HEPA (38.22±3.02), 
 
Fatty Acid 
 (g/100 of total) 
 
CS  
(n=3) 
 
HCHF 
(n=3) 
CEPA 
(n=3) 
 
HEPA 
(n=3) 
C14:0 0.36±0.36 0.73±0.43 0.00±0.00 0.00±0.00 
C16:0 30.67±2.80 28.48±1.65 36.65±1.66 28.71±0.32 
C16:1n-7 1.37±1.37 1.00±0.65 0.00±0.00 0.00±0.00 
C18:0 22.78±4.62 18.15±4.60 25.98±1.22 25.67±2.16 
C18:1n-9 24.61±7.65 34.33±9.35 22.06±0.67 18.21±3.25 
C18:2n-6 6.95±1.64 6.94±1.79 7.97±0.91 9.47±0.51 
C20:4n-6 8.18±2.41 6.37±1.61 4.32±0.25 10.62±1.23 
C20:3n-6 0.28±0.28 0.00±0.00 0.00±0.00 0.36±0.36 
C20:5n-3 0.87±0.47 0.00±0.00 1.83±0.95 0.43±0.43 
C22:6n-3 3.94±1.55bc 4.01±0.96ab 1.18±1.18b 6.53±0.10c 
Total Saturated 53.81±6.02 48.32±6.07 62.64±2.27 54.38±2.43 
Total Unsaturated 46.19±6.02 51.68±6.07 37.36±2.27 45.62±2.43 
Total 
Monounsaturated 
25.98±8.98 36.83±8.09 22.06±2.10 18.21±3.25 
Total Polyunsaturated 20.21±4.90abc 14.84±2.29a 15.30±1.22ac 27.41±0.87b 
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CS (38.11±1.75) and HCHF (32.89±1.14) (Table 8). Total unsaturated fatty acids are 
highest in HCHF (67.11±1.14) with CEPA (52.27±1.29) having the lowest amount 
(Table 9). Of these amounts, 64.14±0.49 (HCHF) and 43.86±7.82 (CEPA) are 
monounsaturated fatty acids (Table 8).  
Differences in fatty acid composition between the CS group and the treatment group 
(CEPA) (p<0.05) also occurred. However, there was no difference found between 
the HCHF and HEPA groups. For example, oleic acid (C18:1) decreased between 
CS (46.52±1.46) and CEPA (25.94±10.92) (p<0.05), but were similar in HCHF 
(59.31±1.13) and HEPA (58.12±0.85) (Table 8). Total saturated fatty acid increased 
from the CS (38.11±1.75) to the CEPA (47.74±1.28) groups, while total unsaturated 
fatty acid levels decreased with CS (57.6±1.75) to CEPA (52.27±1.29), this mainly 
being a decrease in monounsaturated fatty acid levels of 52.22±2.28 (CS) to 
43.86±7.82 (CEPA) (Table 8).  
In the HCHF and HEPA groups, total saturated fatty acids increased from 
32.89±1.14 (HCHF) to 38.22±3.02 (HEPA), total unsaturated fatty acids decreased 
from 67.11±1.14 (HCHF) to 61.78±3.02 (HEPA) with a corresponding decrease in 
MUFA of 64.14±0.49 (HCHF) to 59.41±1.95 (HEPA) (Table 8). 
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Table 8. Adipose (retroperitoneal fat) fatty acid composition in groups fed CS, HCHF, CEPA and HEPA diets 
using H2SO4 derivatization method. 
 
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row with unlike 
superscript are significantly different. P <0.05. No superscripts within a row indicate no significant differences between groups. 
 
 
There was no difference (p<0.05) between any of the fatty acids in the adipose 
tissue despite the diet given when using the BF3 derivatization method. Oleic acid 
(C18:1n-9) was the most abundant fatty acid with (61.90±10.52) and HEPA 
(61.06±0.48) levels higher than in the CS (38.74±10.69) and CEPA (40.76±2.58) 
(Table 9). Palmitic acid (C16:0) was the next highest with HCHF (23.02±4.88) and 
HEPA (22.98±0.22) levels lower than in the CS (32.11±4.32) and CEPA (6.88±0.50) 
(Table 9). Both CS (2.98±2.97) and CEPA (0.17±0.17) had low levels of arachidonic 
acid (C20:4n-6) while the HCHF and HEPA groups had none (Table 9). EPA 
(C20:5n-3) was found in the CEPA (0.44±0.44) group but no others (Table 9). DHA 
(C22:6n-3) was in CS (2.44±2.00), HCHF (0.19±0.18) and CEPA (0.40±0.40) (Table 
9). Total saturated fatty acids were higher in the CS (44.62±5.77) and CEPA 
Fatty Acid 
(g/100 of total) 
CS 
(n=3) 
HCHF 
(n=3) 
 
CEPA 
(n=3) 
HEPA 
(n=3) 
C14:0 2.10±0.10
ab 3.62±0.54b 1.37±0.72a 3.10±0.15ab 
C16:0 32.85±1.12 23.90±0.72 33.90±4.25 26.51±2.67 
C16:1n-7 5.70±0.82 1.79±0.94 14.65±12.11 0.00±0.00 
C18:0 3.16±0.60 5.37±0.93 12.47±6.11 8.61±0.97 
C18:1n-9 46.52±1.46
a 59.31±1.13a 25.94±10.92b 58.12±0.85a 
C18:2n-6 5.38±1.54 2.78±0.60 3.49±1.92 2.37±1.19 
C20:4n-6 0.00±0.00 0.18±0.18 3.87±3.87 0.00±0.00 
C22:6n-3 0.00±0.00 0.00±0.00 1.05±1.04 0.00±0.00 
Total Saturated 38.11±1.75
bc 32.89±1.14bc 47.74±1.28a 38.22±3.02b 
Total Unsaturated 57.6±1.75
ab 67.11±1.14ab 52.27±1.29c 61.78±3.02a 
Total 
Monounsaturated 
52.22±2.28ab 64.14±0.49b 43.86±7.82a 59.41±1.95ab 
Total 
Polyunsaturated 
5.38±1.54 2.97±0.71 8.41±6.57 2.37±1.19 
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(42.44±5.41), while the total unsaturated fatty acids were higher in the HCHF 
(69.72±5.41) and HEPA (64.54±0.49) groups (Table 9). Monounsaturated fatty acids 
were higher across all four groups compared to polyunsaturated fatty acids (Table 9). 
 
Table 8. Adipose (retroperitoneal fat) fatty acid composition in groups fed CS, HCHF, CEPA and HEPA diets 
using BF3 derivatization method.  
 
Each value is a mean±SEM. Number of repetitive experiments indicated within parenthesis. Means within a row 
with unlike superscript are significantly different. P <0.05. No superscripts within a row indicate no significant 
differences between groups. 
  
 
 
Fatty Acid 
(g/100 of total) 
 
 
CS 
(n=3) 
 
 
HCHF 
(n=3) 
 
 
CEPA 
(n=3) 
 
 
HEPA 
(n=3) 
 
C14:0 
 
1.17±0.59 
 
3.39±1.01 
 
2.03±0.13 
 
2.55±0.20 
C16:0 32.11±4.32 23.02±4.88 35.94±3.35 22.98±0.22 
C16:1n-7 4.01±2.14 2.89±1.94 6.88±0.50 1.15±0.58 
C18:0 11.27±5.42 3.89±1.95 4.46±2.37 9.38±0.86 
C18:1n-9 38.74±10.69 61.90±10.52 40.76±2.58 61.06±0.48 
C18:2n-6 6.06±3.05 3.57±2.56 5.98±3.24 2.32±0.48 
C20:0 0.06±0.06 0.00±0.00 0.00±0.00 0.56±0.28 
C20:4n-6 2.98±2.97 0.00±0.00 0.17±0.17 0.00±0.00 
C20:5n-3 0.00±0.00 0.00±0.00 0.44±0.44 0.00±0.00 
C22:6n-6 2.44±2.00 0.19±0.18 0.40±0.40 0.00±0.00 
Total Saturated 44.62±5.77 30.30±5.40 42.44±5.41 35.46±0.49 
Total Unsaturated 55.38±5.77 69.72±5.41 57.56±5.41 64.54±0.49 
Total Monounsaturated 43.90±12.16 65.94±8.05 50.57±2.98 62.22±0.96 
 
Total Polyunsaturated 11.48±7.32 3.76±2.73 6.99±3.40 2.32±0.48 
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CHAPTER 4 
DISCUSSION 
4.1 Analysis of Method 
The generation of fatty acid methyl esters (FAMEs) is necessary for the analysis of 
long chain fatty acids (>C12) by gas chromatography. The separation of the 
carboxylic acids is complicated by their relatively high polarity, so relatively nonpolar 
derivatives, such as FAMEs, which are more volatile are produced. FAME can be 
produced using acidic or alkaline conditions (Ruiz-Rodriguez et al., 2010), this 
project utilized the acidic conditions produced by heating fats with an excess of 
methanol in the presence of either H2SO4 or BF3 catalysts. While both methods 
produced FAME there were a number of noteworthy differences. 
 4.1.1 Sulphuric Acid (H2SO4) method 
This method is a very simple method to use as only two chemicals (H2SO4 and 
Methanol) are involved in the derivatization process and it only uses diethyl ether 
and distilled water in the separation and extraction process. It is neither expensive 
nor dangerous and has good GC response (Antolin et al., 2008).  Another advantage 
is that sufficient FAME is produced to enable multiple analyses. However, a number 
of limitations were also found to exist with this method.  While the method was 
suitable for large scale samples, when it was scaled down to test tube amounts the 
sample regularly discoloured. This may have been due to the methanol solvent 
evaporating too quickly and the residual H2SO4 charring the fatty acid and is 
problematic in achieving optimum results as FAMEs may not be produced. The hot 
plate used in this procedure was a limitation as it did not heat accurately, with 
temperatures varying as it could not be set specifically at 65°C to enable the reaction 
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to take place at the optimum temperature. These issues could be solved by using a 
water bath that is set at a consistent temperature.  
Another limitation is the length of time that the derivatization process takes, as each 
sample takes at least 2 hours followed by the extraction and separation process this 
limits the number of samples that can be prepared at any one time. However, 
previous research has indicated that the process can take as little as 10 minutes with 
the addition of further chemicals (n-hexane, 1 M sodium hydroxide), higher 
temperature and occasional shaking (Antolin et al., 2008). 
A large volume of chemicals are need for this method, particularly the separation and 
extraction processes. Even in the small scale experiments 30 mL of diethyl ether and 
40 mL of water was required.  
During the separation and extraction phase of the method, there is the possibility of 
losing sample through spillage, or remaining in the glassware used.  
4.1.2 BF3 Method 
 
The BF3 method allows for fast and effective methylation (Antolin et al., 2008, Ruiz-
Rodriguez et al., 2010), as multiple samples were able to be prepared 
simultaneously enabling analysis by GC-MS to occur sooner. Temperature was 
controlled at a steady 95°C using a water bath, which controlled solvent evaporation. 
As BF3 is volatile the need for a more complicated work up procedure is removed. 
However, limitations exist as the reagent is expensive and doesn’t have a long shelf 
life even when refrigerated (Antolin et al., 2008). BF3 has greater toxicity, 
consequently greater care needed to be taken during the procedure. Also only 
sufficient FAME was produced for a single GC-MS auto sampler vial to be prepared. 
There have also been reports that BF3 leads to irreversible damage of the GC 
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column (Ruiz-Rodriguez et al., 2010), which is another consideration to make when 
using this method.  
4.1.3 Comparison of results  
The results obtained confirm that both BF3-methanol and H2SO4-methanol 
derivatization methods are suitable to use for the analysis of fatty acids.  The results 
achieved from both liver and adipose tissue samples indicate that there was no 
significant difference (p>0.05) between the methods (Figure 11) therefore no 
definitive conclusion, can be made as to the method better suited to the 
derivatization process. Therefore in considering that one of the objectives of this 
project is to validate previous results (Poudyal et al., 2012b), comparisons will be 
made using the BF3 methodology results as this is the more accepted method of 
derivatization in prior literature. Comparisons will be made between the two methods 
where appropriate.  
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Figure 11. Derivatization Method Comparison (BF3 vs. H2SO4) in various feeding conditions (CS, 
HCHF, CEPA, HEPA) in adipose (a-d) and liver (e-h) tissue. 
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4.2 Analysis of Treatments 
 
Plant and animal oils were tested for method validation purposes as well to identify 
fatty acid compounds that were present. As samples were of relative purity they 
could be compared to other literature and used to validate the methodology of this 
project. These oils were analysed using the H2SO4 method due to ease of use in 
bulk samples and cost considerations.  
4.2.1 Plant Oils  
 
Plant oils consist mainly of unsaturated fatty acids. Chia, flax and safflower oils have 
high levels of polyunsaturated fatty acids (PUFA) (Figure 13). Olive, macadamia, 
avocado and canola oils consist mainly of monounsaturated fatty acids (MUFA) 
(Figure 13).  Safflower, olive and avocado oils have the highest levels of saturated 
fatty acids (SFA) (Figure 13) amongst the plant oils that were tested. Oleic acid and 
linoleic acid were found in all samples. Oleic acid is the predominant dietary MUFA 
(Asif, 2011) found in plants, results indicated it was highest in macadamia oil, 
followed by canola, olive and avocado, with low levels found in chia and safflower 
(Figure 12). Linoleic acid was highest in the safflower sample with varying levels in 
all other samples (Figure 12).  α-linolenic acid was found in flax, chia and a low level 
in macadamia (Figure 12). The typical ‘western’ diet contains much more linoleic 
acid than α-linolenic acid (Gillingham et al., 2011). Both linoleic and α-linolenic acids 
are eicosanoid precursors with linoleic acid ones tending to be pro-inflammatory and 
α-linolenic acid ones anti-inflammatory (Poudyal et al., 2011) indicating possible 
implications in the development of obesity.  
 A very small amount of arachidonic acid was found in chia and canola (Figure 12) 
indicating elongation from linoleic acid. (Individual plant oil graphs see Appendix 1).  
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Figure 12. Individual fatty acid composition of plant oils. 
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Figure 13. Total fatty acid composition of plant oils. 
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Results are comparable to those found in literature (Asif, 2011, Poudyal et al., 2012a, 
Poudyal et al., 2012b) indicating that the methodology used was appropriate. 
However, it must be noted that while types and proportions of fatty acids were similar, 
the overall values were higher possibly due to the extracted samples being used 
being a better quality than metabolised samples as in the literature values which 
were measured after dietary supplementation. It is also possible that values are 
slightly different due to different GC columns being used to analyse the samples or 
to natural variation between the samples themselves.  
4.2.2 Animal Oils 
Animal oils differ in fatty acid composition. The samples of EPA and DHA that were 
examined were essentially ‘pure’. Most studies utilize a mix of EPA/DHA through fish 
oil supplements, capsules or an oily fish diet therefore it is unclear if they have 
independent effects or if the result is due to the mixture.  
Results indicated that the samples of EPA and DHA were both 100% unsaturated 
fatty acids, as expected. EPA consisted mainly of n-3 fatty acids with EPA and a 
small amount of its derivative DHA and also a small amount of C20:4 (Figure 14). 
DHA was found to consist of DHA with low levels of its precursor EPA and C20:4 
(Figure 14).  It was not clear from our analysis whether the C20:4 was the pro-
inflammatory arachidonic acid (C20:4n-6), or the anti-inflammatory eicosatetranoic 
acid (C20:4n-3). However, previous studies on EPA have found it to be involved in 
the production of anti-inflammatory eicosanoids (Bagga et al., 2003, Duda et al., 
2009, Feller and Gawrisch, 2005, Poudyal et al., 2012b, Schmitz and Ecker, 2008, 
Yashodhara et al., 2009), therefore it may be postulated that it is C20:4n-3 as it is a 
precursor to EPA.  
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The beef tallow that was tested was found to contain mostly SFA, particularly 
palmitic (C16:0) and stearic (C18:0) acids. A lower amount of UFA, was found with 
oleic (C18:1) being the main fatty acid and a low level of LA (C18:2n-6) (Figure 15).   
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Figure 14. Individual fatty acids composing animal oils (EPA, DHA and beef tallow). 
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Figure 15. Total fatty acid composition of animal oils (EPA, DHA and beef tallow). 
 
Animals are unable to produce fatty acids over than C18:1 due to a lack of 
necessary enzymes, therefore cannot form linoleic acid (C18:2n-6), α-linolenic acid 
(C18:3n-3) or longer fatty acids de novo. However, animals can further extend 
linoleic (C18:2n-6) and α-linolenic acids (C18:3n-3), so they are essential to 
metabolism and are only gained from external sources, such as plants (Poudyal et 
al., 2012a). 
Plant and animal oil results are similar to other research undertaken (Poudyal et al., 
2012a)  indicating that the H2SO4 method is viable, particularly when done on a 
large scale to provide sufficient fatty acids to be converted to FAME for GC-MS 
analysis.  
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4.3 Analysis of Tissue Samples  
 
4.3.1 Tissue Samples 
 
Most biological tissues are involved in fatty acid metabolism with the liver and 
adipose tissue the most important (Frayn et al., 2006). Adipose fatty acids are 
released to circulate to other tissues, while liver fatty acids act as a substrate for re-
esterification within the endoplasmic reticulum to make triacylglycerol and to be 
secreted as very low density lipoprotein (VLDL) (Frayn et al., 2006). Evidence from 
previous studies suggests that individual fatty acids may have selective and 
potentially independent effects on cardiovascular health, (Li et al., 2008, Poudyal et 
al., 2011) whether this extends to attenuation of obesity-related symptoms is still 
relatively unknown.  
Liver (n=3) and adipose/retroperitoneal fat (n=3) tissue samples from the HCHF rat 
model of obesity were examined for differences in fatty acid composition between 
diet and also with supplementation of ‘pure’ EPA. 
 
4.3.1.1 Liver Samples 
 
Studies indicate that dietary EPA partially replaces the n-6 PUFA’s from various cells 
including hepatocytes by inhibiting stearoyl-CoA-desaturase-1 (SCD-1) (Simopoulos, 
2002). Of the four SCD genes that have been discovered SCD-1 is the only 
desaturase expressed by the liver (Li et al., 2008). The conversion of n-3 and n-6 
fatty acids share the same series of enzymes and competition exists for metabolism 
with an excess of one causing a significant decrease in the conversion of the other. 
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(Schmitz and Ecker, 2008). If n-3 fatty acids can be detected at higher levels than n-
6 fatty acids, then the conversion to anti-inflammatory eicosanoids is possible. 
There was a slight increase in palmitic acid (C16:0) in the CEPA group compared to 
CS, while there was a low level of palmitoleic acid (C16:1) in the supplementation 
groups, (Figure 16) indicating the possible inhibition of SCD-1, as this enzyme 
induces as cis-double bond in the Δ9 position, and is the rate limiting factor in the 
biosynthesis of MUFA (Li et al., 2008). Similarly oleic acid (C18:1) was lower in the 
CEPA and HEPA fed liver sample (Figure 16).  
DGLA (C20:3n-6) was found in low levels in CS and CEPA groups (Figure 17). 
DGLA is an intermediary to arachidonic acid (C20:4n-6) which is the key 
intermediate in the production of pro-inflammatory eicosanoid metabolites (TX2, 
PG2, LT4) (Serhan et al., 2007).  DHA (C22:6) was found to be higher in HEPA than 
HCHF and EPA (C20:5) was higher in CEPA than CS (Figure 17), both these results 
are as expected with the supplementation of EPA into the diet. 
Total SFA increased between the diet and supplementation groups, while the total 
UFA decreased (Figure 17), in line with SCD-1 being inhibited.  PUFA decreased 
from the CS to the CEPA groups and increased from the HCHF to the HEPA group 
(Figure 17). Studies have found that high fish oil feeding decreases liver fatty acid 
synthase (FAS) and SCD-1 expression (Sun et al., 2011) for example Inuit and 
Japanese diets are high in fish-derived EPA and DHA (Greene et al., 2013, Li et al., 
2008). However, the incidence of obesity is low, suggesting there may be a 
beneficial effect of n-3 PUFA enriched fish oil in preventing and alleviating obesity.  
Engler et al. (2000) found that in spontaneously hypertensive rats that a DHA 
enriched diet for 6 weeks decreased the Δ9 desaturase in hepatic microsomes, and 
was accompanied by an increase in palmitic acid and decrease in palmitoleic acid. 
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As MUFA make up a large portion of cellular lipids the decrease in their biosynthesis 
via SCD inhibition may account for PUFA fat lowering effects.  
 
a. 
   
  
fa
tt
y 
ac
id
 c
o
n
te
n
t
(g
/1
00
g
)
C
16
:0
C
16
:1
 
b. 
   
  
fa
tt
y
 a
c
id
 c
o
n
te
n
t
(g
/1
0
0
g
)
C
1
8
:0
C
1
8
:1
 
Figure 16. Comparison of (a) C 16:0 and C16:1 (b) C18:0 and C18:1 levels in liver under CS, HCHF, CEPA and 
HEPA feeding conditions. 
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Figure 17. Fatty acid content of liver under CS, HCHF, CEPA and HEPA feeding conditions. (a) C16:0 (b) C16:1 
(c) C18:0 (d) C18:1 (e) C18:2 (f) C20:3 (g) C20:4 (h) C20:5 (i) C22:6 (j) Total SFA (k) Total UFA (l) total MUFA 
(m) Total PUFA      
 
 
4.3.1.2 Adipose Samples  
 
Dietary fatty acids are an important source of adipose tissue fatty acids and not just 
the amount but also the composition plays a significant role in adipose tissue 
metabolism. (Fernández-Quintela et al., 2007). Adipose tissue is seen as a reliable 
biomarker for long term dietary intake due to its ability to store fatty acids for up to 2 
years (Iggman et al., 2010), especially for the essential fatty acids: linoleic and α-
linolenic acids, as well as EPA and DHA. However, it is still unclear whether it is an 
appropriate biomarker to indicate the tendency towards obesity-related diseases. 
 Although experiments yielded no significant differences (P>0.05), there were a 
number of trends emerging, that correlate with previous research (Poudyal et al., 
2012b). Palmitic (C16:0) and oleic (C18:1n-3) acids had the highest levels with slight 
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increases between the CS to CEPA groups and decreases from HCHF to HEPA 
groups (Figure 18), as with the liver samples this could possibly be due to EPA 
inhibiting the enzymatic activity of SCD-1.  Stearic acid (C18:0) decreased in the 
CEPA group compared to the CS group, while there was an increase in the HEPA 
group compared to the HCHF group (Figure 18).    
 An increased amount of EPA was found in CEPA compared to the dietary CS group, 
as expected with dietary supplementation. A minimal amount appears to have been 
converted to DHA in the CEPA supplementation group (Figure 18).  A larger 
difference was found between EPA and DHA in the HEPA supplementation group, 
suggesting that increased conversion occurred (Figure 18).  As there is no α-linolenic 
acid present in any of the groups examined, it is assumed that the EPA and DHA 
comes from the diet. There is also the assumption that the linoleic acid that appears 
is the key precursor to the arachidonic acid found in all groups (Figure 18), which 
may lead to preferential metabolism of pro-inflammatory eicosanoids. 
 Previous research (Poudyal et al., 2012b) using rats on the same diet, indicated α-
linolenic acid was present, this is contradictory to current results, possibly due to 
differences in the GC-MS columns used. Changes in the methodology are warranted 
to specifically quantify α-linolenic acid particularly the use of a fatty acid specific 
column such as the Agilent DB-23.  
Total SFA marginally decreased between CS and CEPA, and increased between 
HCHF and HEPA (Figure 18).  A corresponding change in unsaturated fatty acid 
composition appeared with slight increases between CS and CEPA and decreases 
between HCHF and HEPA (Figure 18). MUFA increased in CEPA and decreased in 
HEPA, while PUFA decreased in both supplementation groups. Overall UFA, and 
MUFA, was higher in the HCHF and HEPA groups while PUFA and SFA were higher 
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in the CS and CEPA groups (Figure 18). Studies have found that fish oil enriched 
diets prevent abdominal fat accumulation compared to other dietary oils, suggesting 
that n-3 PUFA supplements play an important role in preventing weight gain and 
improving weight loss (Micallef et al., 2009). 
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Figure 18. Fatty acid content of adipose tissue under various feeding conditions. (a) C16:0 (b) C16:1 (c) C18:0 
(d) C18:1 (e) C18:2 (f) C20:0 (g) C20:4 (h) C20:5 (i) C22:6 (j) Total SFA (k) Total unsaturated fatty acid (l) Total 
MUFA (m) Total PUFA 
 
 
Studies show that EPA and DHA ameliorate obesity-induced inflammation (Poudyal 
et al., 2012b, Schmitz and Ecker, 2008) and with increased levels of EPA and DHA 
in the liver samples between the diet (CS) and supplementation (CEPA) groups, and 
decreased levels between the HCHF and HEPA groups in the adipose tissue there is 
an indication that it is being utilized by the body to reduce the obesity-related 
inflammation.   
Results from the liver and adipose tissue samples indicate that very little EPA is 
being deposited in the liver while more was found in the adipose tissue, this may 
indicate that it is being desaturated and elongated into DHA or it could also be 
metabolized into energy.  
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There is the possibility that supplementation of the diet with EPA is inhibiting the 
enzymatic activity of SCD-1 to elongate and desaturate linoleic acid to arachidonic 
acid. This could provide some evidence supporting the beneficial effects of DHA and 
EPA on improving obesity. 
 
4.4 Limitations 
A number of limitations exist with this research project. Firstly, the sample size was 
limited to n=3 per oil and tissue type, for more conclusive results a larger sample 
size is necessary.  Secondly, the GC column that was used was not specifically 
made for fatty acid analysis, therefore issues arose with separation of fatty acids e.g. 
C18 series cis- and trans- isomers of C18:1 eluted together. A more suitable column 
to use would be the DB23 High-polarity column produced by Agilent, as it is 
specifically designed for the analysis of fatty acid methyl esters (FAMEs) and 
provides excellent resolution for cis- and trans- isomers with very little overlap of 
FAMEs of the same chain length (Agilent, 2013).  
 
4.5 Future Directions 
There are a number of different directions that future research could take including 
the following:  
• Further research could be undertaken using individual oils, particularly 
avocado, macadamia and canola to determine their capacity to affect obesity 
as these have yet to be fully explored. This would complement previous 
studies done on the effects of chia seed oil (Poudyal et al., 2012a), EPA and 
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DHA (Poudyal et al., 2012b)  where the focus of the research was on 
cardiovascular health.  
• Further research needs to be undertaken in this area to determine which fatty 
acids could be utilized as biomarkers to suggest that a person is at risk of 
developing serious diseases as a consequence of being obese. However, to 
do this it would possibly be more beneficial to use plasma samples, 
particularly in human trials as they are more readily accessible. If plasma 
samples were to be used then further studies using the rat model of obesity 
may be necessary first to ensure that the most appropriate biomarkers are 
studied. Arachidonic acid could possibly be used as a biomarker in liver and 
adipose samples although this would be more difficult to achieve in humans.  
• The pro-inflammatory eicosanoids, for which arachidonic acid is a precursor 
could possibly be used as a biomarker for obesity related diseases. It is also 
possible that the anti-inflammatory eicosanoids could be investigated, 
focusing on EPA as the key intermediate. Research into the two essential 
fatty acids and their relationship to obesity could possibly be an area of 
interest with an increase of linoleic acid tending towards pro-inflammatory 
eicosanoids or increases in α-linolenic acid towards the anti-inflammatory 
eicosanoids. Investigations of the n-6:n-3 ratio - LA:ALA and also AA:EPA 
• Future studies could also continue to investigate the fatty acid profiles of other 
tissues, such as plasma, whole blood, and heart, as well as investigating 
faecal and urine samples to gain an understanding of the entire ‘journey’ of 
fatty acid from food through metabolism to excretion. This could be extended 
to describe how the profiles differ for each fatty acid at each stage of the 
journey.   
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CHAPTER 5 
CONCLUSION 
 
Results achieved by this project are consistent with previous plasma and 
cardiovascular fatty acid composition studies (Poudyal et al., 2012b). This research 
goes someway to filling the gap by utilizing liver and adipose (retroperitoneal fat) 
tissue to elucidate the fatty acid composition further by using rats on the same diet 
and supplementation of EPA. Previous studies have indicated that EPA and DHA 
ameliorate obesity-related inflammation (Poudyal et al., 2012b, Schmitz and Ecker, 
2008). Current results indicate that EPA levels increased in liver samples between 
the diet (CS and HCHF) groups and the supplementation (CEPA and HEPA) groups, 
while having a corresponding decrease in adipose tissue, possibly indicating that the 
EPA is being utilized by the body to reduce obesity related inflammation. There is the 
possibility that by supplementing the diet with EPA it is inhibiting the enzymatic 
activity of SCD-1 to elongate and desaturate linoleic acid to arachidonic acid, as 
indicated by decreased levels of arachidonic acid in the CEPA groups of both the 
liver and adipose tissue samples, providing some evidence supporting the beneficial 
effects of DHA and EPA on improving obesity.  
In conclusion, results appear to confirm that while the quantity of fat that is 
consumed leads to obesity it is more likely that it is the quality of fat that is the final 
determining factor in whether obesity-related diseases become apparent. 
  
 
 
74 
 
REFERENCES 
AGILENT. 2013. GC & GC/MS Columns  DB-23 [Online]. Available: http://www.chem.agilent.com/. 
AILHAUD, G., GUESNET, P. & CUNNANE, S. 2008. An emerging risk factor for obesity: does 
disequilibrium of polyunsaturated fatty acid metabolism contribute to excessive adipose tissue 
development? British Journal of Nutrition, 100, 461-70. 
ANTOLIN, E. M., DELANGE, D. M. & CANAVACIOLO, V. G. 2008. Evaluation of five methods for 
derivatization and GC determination of a mixture of very long chain fatty acids (C24:0-C36:0). Journal 
of Pharmaceutical and  Biomedical Analysis, 46, 194-9. 
ARAUJO, P., NGUYEN, T. T., FROYLAND, L., WANG, J. & KANG, J. X. 2008. Evaluation of a rapid 
method for the quantitative analysis of fatty acids in various matrices. Journal of Chromatography A, 
1212, 106-13. 
ARITA, M., BIANCHINI, F., ALIBERTI, J., SHER, A., CHIANG, N., HONG, S., YANG, R., PETASIS, N. A. & 
SERHAN, C. N. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the 
omega-3 lipid mediator resolvin E1. The Journal of Experimental Medicine, 201, 713-722. 
ASIF, M. 2011. Health effects of omega-3,6,9 fatty acids: Perilla frutescens is a good example of plant 
oils. Oriental Pharmacy & Experimental Medicine, 11, 51-59. 
BAGGA, D., WANG, L., FARIAS-EISNER, R., GLASPY, J. A. & REDDY, S. T. 2003. Differential effects of 
prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 
secretion. Proceedings of the National Academy of Sciences, 100, 1751-1756. 
BAYLIN, A., KABAGAMBE, E. K., SILES, X. & CAMPOS, H. 2002. Adipose tissue biomarkers of fatty acid 
intake. American Journal of Clinical Nutrition, 76, 750-757. 
BLIGH, E. G. & DYER, W. J. 1959. A rapid method of total lipid extraction and purification Canadian 
Journal of Biochemistry and Physiology, 37, 911-917. 
CAO, H., GERHOLD, K., MAYERS, J. R., WIEST, M. M., WATKINS, S. M. & HOTAMISLIGIL, G. S. 2008. 
Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism. Cell, 
134, 933-944. 
CARRAPISO, A. & GARCIA, C. 2000. Development in Lipid Analysis: Some new extraction techniques 
and in situ transesterification. Lipids, 35, 1167-1177. 
CONSITT, L. A., BELL, J. A. & HOUMARD, J. A. 2009. Intramuscular lipid metabolism, insulin action, 
and obesity. IUBMB Life, 61, 47-55. 
DUDA, M. K., O'SHEA, K. M. & STANLEY, W. C. 2009. ω-3 polyunsaturated fatty acid supplementation 
for the treatment of heart failure: mechanisms and clinical potential. Cardiovascular Research, 84, 
33-41. 
ECKER, J., LIEBISCH, G., ENGLMAIER, M., GRANDL, M., ROBENEK, H. & SCHMITZ, G. 2010a. Induction 
of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. 
Proceedings of the National Academy of Sciences, 107, 7817-22. 
ECKER, J., LIEBISCH, G., SCHERER, M. & SCHMITZ, G. 2010b. Differential effects of conjugated linoleic 
acid isomers on macrophage glycerophospholipid metabolism. Journal of Lipid Research, 51, 2686-
94. 
ECKER, J., SCHERER, M., SCHMITZ, G. & LIEBISCH, G. 2012. A rapid GC-MS method for quantification 
of positional and geometric isomers of fatty acid methyl esters. Journal of Chromatography B, 897, 
98-104. 
ENGLER, M., BELLENGER-GERMAIN, S., ENGLER, M., NARCE, M. & POISSON, J.-P. 2000. Dietary 
docosahexaenoic acid affects stearic acid desaturation in spontaneously hypertensive rats. Lipids, 
35, 1011-1015. 
ESCOUBET, B., GRIFFATON, G., GUESNET, P., LECHAT, P. & LAVAU, M. 1987. Prostaglandin synthesis 
and membrane fatty acid composition in the heart of obese Zucker rats. Biochemical and Biophysical 
Research Communications, 146, 589-595. 
FELLER, S. E. & GAWRISCH, K. 2005. Properties of docosahexaenoic-acid-containing lipids and their 
influence on the function of rhodopsin. Current Opinion in Structural Biology, 15, 416-422. 
 
 
75 
 
FERNÁNDEZ-QUINTELA, A., CHURRUCA, I. & PORTILLO, M. P. 2007. The role of dietary fat in adipose 
tissue metabolism. Public Health Nutrition, 10, 1126-1131. 
FOLCH, J., LEES, M. & SLOANE STANLEY, G. 1957. A simple method for the isolation and purification 
of total lipids from animal tissues. Journal of Biological Chemistry, 226, 497-509. 
FRAYN, K., ARNER, P. & YKI-JARVINEN, H. 2006. Fatty acid metabolism in adipose tissue, muscle and 
liver in health and disease. Essays in Biochemistry. London: Portland Press Ltd. 
FUHRMAN, B. J., BARBA, M., KROGH, V., MICHELI, A., PALA, V., LAURIA, R., CHAJES, V., RIBOLI, E., 
SIERI, S., BERRINO, F. & MUTI, P. 2006. Erythrocyte membrane phospholipid composition as a 
biomarker of dietary fat. Annals of Nutrition and Metabolism, 50, 95-102. 
GILLINGHAM, L., HARRIS-JANZ, S. & JONES, P. H. 2011. Dietary Monounsaturated Fatty Acids Are 
Protective Against Metabolic Syndrome and Cardiovascular Disease Risk Factors. Lipids, 46, 209-228. 
GREENE, J., ASHBURN, S. M., RAZZOUK, L. & SMITH, D. A. 2013. Fish Oils, Coronary Heart Disease, 
and the Environment. American Journal of Public Health, 103, 1568-1576. 
HARRIS, W. S. & VON SCHACKY, C. 2004. The Omega-3 Index: a new risk factor for death from 
coronary heart disease? Preventive Medicine, 39, 212-220. 
HASLAM, D. W. & JAMES, W. P. T. 2005. Obesity. The Lancet. 1197-1209 ed. 
HE, Q., REN, P., KONG, X., WU, Y., WU, G., LI, P., HAO, F., TANG, H., BLACHIER, F. & YIN, Y. 2012. 
Comparison of serum metabolite compositions between obese and lean growing pigs using an NMR-
based metabonomic approach. The Journal of Nutritional Biochemistry, 23, 133-139. 
IGGMAN, D., ÄRNLÖV, J., VESSBY, B., CEDERHOLM, T., SJÖGREN, P. & RISÉRUS, U. 2010. Adipose 
tissue fatty acids and insulin sensitivity in elderly men. Diabetologia, 53, 850-857. 
KIM, H.-J., KIM, J. H., NOH, S., HUR, H. J., SUNG, M. J., HWANG, J.-T., PARK, J. H., YANG, H. J., KIM, 
M.-S., KWON, D. Y. & YOON, S. H. 2010. Metabolomic Analysis of Livers and Serum from High-Fat 
Diet Induced Obese Mice. Journal of Proteome Research, 10, 722-731. 
KING, I., LEMAITRE, R. & KESTIN, M. 2006. Effect of a low-fat diet on fatty acid composition in red 
cells, plasma phospholipids, and cholesterol esters: Investigation of a biomarker of total fat intake. 
American Journal of Clinical Nutrition, 83, 227-236. 
LI, J.-J., HUANG, C. J. & XIE, D. 2008. Anti-obesity effects of conjugated linoleic acid, docosahexaenoic 
acid, and eicosapentaenoic acid. Molecular Nutrition & Food Research, 52, 631-645. 
MAJOR, H. J., WILLIAMS, R., WILSON, A. J. & WILSON, I. D. 2006. A metabonomic analysis of plasma 
from Zucker rat strains using gas chromatography/mass spectrometry and pattern recognition. Rapid 
Communication in Mass Spectrometry, 20, 3295-302. 
MASOOD, M. A. & SALEM, N., JR. 2008. High-Throughput Analysis of Plasma Fatty Acid Methyl Esters 
Employing Robotic Transesterification and Fast Gas Chromatography. Lipids, 43, 171-180. 
MICALLEF, M., MUNRO, I., PHANG, M. & GARG, M. 2009. Plasma n-3 polyunsaturated fatty acids are 
negatively associated with obesity. British Journal of Nutrition, 102, 1370-1374. 
MOZAFFARIAN, D., RIMM, E., KING, I., LAWLER, R., MCDONALD, G. & LEVY, W. 2004. Trans fatty 
acids and systemic inflammation in heart failure. American Journal of Clinical Nutrition, 80, 1521-
1525. 
MUOIO, D. M. 2010. Metabolism and Vascular Fatty Acid Transport. New England Journal of 
Medicine, 363, 291-293. 
NELSON, G. J., KELLY, D. S., EMKEN, E. A., PHINNEY, S. D., KYLE, D. & FERRETTI, A. 1997. A human 
dietary arachidonic acid supplementation study conducted in a metabolic research unit: Radionale 
and design. Lipids, 32, 415-420. 
NOVGORODTSEVA, T. P., KARAMAN, Y. K., ZHUKOVA, N. V., LOBANOVA, E. G., ANTONYUK, M. V. & 
KANTUR, T. A. 2011. Composition of fatty acids in plasma and erythrocytes and eicosanoids level in 
patients with metabolic syndrome. Lipids in Health and Disease 10, 82-87. 
ODEGAARD, A. O. & PEREIRA, M. A. 2006. Trans fatty acids, insulin resistance, and type 2 diabetes. 
Nutrition Reviews, 64, 364-372. 
PARK, Y. W., CHANG, P.-S. & LEE, J. 2010. Application of triacylglycerol and fatty acid analyses to 
discriminate blended sesame oil with soybean oil. Food Chemistry, 123, 377-383. 
 
 
76 
 
POIRIER, P. 2007. Adiposity and cardiovascular disease: are we using the right definition of obesity? 
European Heart Journal, 28, 2047-2048. 
POPPITT, S., KILMARTIN, P., BUTLER, P. & KEOGH, G. 2005. Assessment of erythrocyte phospholipid 
fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a 
controlled cross-over intervention trial. Lipids in Health and Disease, 4, 30. 
POUDYAL, H. & BROWN, L. 2013. The Role of n-3 Polyunsaturated Fatty Acids in Human Heart 
Failure. Endocrine, Metabolic & Immune Disorders - Drug Targets, 13, 105-117. 
POUDYAL, H., KUMAR, S. A., IYER, A., WAANDERS, J., WARD, L. C. & BROWN, L. 2013. Responses to 
oleic, linoleic and alpha-linolenic acids in high-carbohydrate, high-fat diet-induced metabolic 
syndrome in rats. Journal of Nutritional Biochemistry. 
POUDYAL, H., PANCHAL, S., WAANDERS, J., WARD, L. & BROWN, L. 2012a. Lipid redistribution by 
alpha-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and 
hepatic protection in diet-induced obese rats. The Journal of Nutritional Biochemistry, 23, 153-62. 
POUDYAL, H., PANCHAL, S., WARD, L. & BROWN, L. 2012b. Effects of ALA, EPA and DHA in high-
carbohydrate, high-fat diet-induced metabolic syndrome in rats. The Journal of Nutritional 
Biochemistry. 
POUDYAL, H., PANCHAL, S. K., DIWAN, V. & BROWN, L. 2011. Omega-3 fatty acids and metabolic 
syndrome: Effects and emerging mechanisms of action. Progress in Lipid Research, 50, 372-387. 
QUEHENBERGER, O. & DENNIS, E. A. 2011. The Human Plasma Lipidome. New England Journal of 
Medicine, 365, 1812-1823. 
RETT, B. & WHELAN, J. 2011. Increasing dietary linoleic acid does not increase tissue arachidonic acid 
content in adults consuming Western-type diets: a systematic review. Nutrition & Metabolism, 8, 36. 
ROBINSON, L. E., BUCHHOLZ, A. C. & MAZURAK, V. C. 2007. Inflammation, obesity, and fatty acid 
metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic 
syndrome. Applied Physiology, Nutrition & Metabolism, 32, 1008-1024. 
ROSITO, G. A., MASSARO, J. M., HOFFMANN, U., RUBERG, F. L., MAHABADI, A. A., VASAN, R. S., 
O’DONNELL, C. J. & FOX, C. S. 2008. Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease 
Risk Factors, and Vascular Calcification in a Community-Based Sample: The Framingham Heart Study. 
Circulation, 117, 605-613. 
RUIZ-RODRIGUEZ, A., REGLERO, G. & IBANEZ, E. 2010. Recent trends in the advanced analysis of 
bioactive fatty acids. Journal of  Pharmaceutical and  Biomedical  Analysis, 51, 305-26. 
SCHMITZ, G. & ECKER, J. 2008. The opposing effects of n−3 and n−6 fatty acids. Progress in Lipid 
Research, 47, 147-155. 
SERHAN, C. N., LU, Y., HONG, S. & YANG, R. 2007. Mediator Lipidomics: Search Algorithms for 
Eicosanoids, Resolvins, and Protectins. In: BROWN, H. A. (ed.) Methods in Enzymology. Academic 
Press. 
SIMOPOULOS, A. P. 2002. Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases. Journal 
of the American College of Nutrition, 21, 495-505. 
SUN, C., WEI, Z.-W. & LI, Y. 2011. DHA regulates lipogenesis and lipolysis genes in mice adipose and 
liver. Molecular Biology Reports, 38, 731-737. 
THIÉBAUT, A. C. M., ROTIVAL, M., GAUTHIER, E., LENOIR, G. M., BOUTRON-RUAULT, M.-C., JOULIN, 
V., CLAVEL-CHAPELON, F. & CHAJÈS, V. 2009. Correlation Between Serum Phospholipid Fatty Acids 
and Dietary Intakes Assessed a Few Years Earlier. Nutrition and Cancer, 61, 500-509. 
WEI, G.-L. & ZENG, E. Y. 2011. Gas chromatography-mass spectrometry and high-performance liquid 
chromatography-tandem mass spectrometry in quantifying fatty acids. TrAC Trends in Analytical 
Chemistry, 30, 1429-1436. 
WILLIAMS, R., LENZ, E. M., WILSON, A. J., GRANGER, J., WILSON, I. D., MAJOR, H., STUMPF, C. & 
PLUMB, R. 2006. A multi-analytical platform approach to the metabonomic analysis of plasma from 
normal and Zucker (fa/fa) obese rats. Molecular Biosystems, 2, 174-83. 
WORLD HEALTH ORGANISATION, W. 2008. Obesity [Online]. 
Available: http://www.who.int/topics/obesity/en/. 
 
 
77 
 
YASHODHARA, B. M., UMAKANTH, S., PAPPACHAN, J. M., BHAT, S. K., KAMATH, R. & CHOO, B. H. 
2009. Omega-3 fatty acids: a comprehensive review of their role in health and disease. Postgraduate 
Medical Journal, 85, 84-90. 
ZHANG, A., SUN, H. & WANG, X. 2012. Power of metabolomics in biomarker discovery and mining 
mechanisms of obesity. Obesity Reviews, 14, 344-349. 
ZHANG, Q., WANG, G. J., A, J. Y., WU, D., ZHU, L. L., MA, B. & DU, Y. 2009. Application of GC/MS-
based metabonomic profiling in studying the lipid-regulating effects of Ginkgo biloba extract on diet-
induced hyperlipidemia in rats. Acta Pharmacologica Sinica, 30, 1674-87. 
 
 
  
 
 
78 
 
APPENDIX ONE 
 
Graphs of Fatty Acid Content  
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Fatty acid composition of a variety of plant oils (a) chia (b) safflower (c) flax (d) olive (e) macadamia (f) 
avocado (g) canola 
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Individual fatty acid content of a variety of plant oils (a) C16:0 (b) C16:1 (c) C18:0 (d) C18:1 (e) C18:2 
(f) C18:3 (g) C20:4 (h) total SFA (i) total MUFA (j) Total PUFA 
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Fatty acid composition of a variety of animal oils (a) EPA (b) DHA (c) Beef tallow 
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Individual fatty acid content of a variety of animal oils (a) C16:0 (b) C18:0 (c) C18:1 (d) C18:2 (e) 
C20:4 (f) C20:5  (g) C22:6  (h) total SFA (i) total UFA (j) Total MUFA (k) Total PUFA 
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Fatty acid composition of Adipose Tissue in a variety of dietary conditions (a) CS (b) HCHF (c) CEPA 
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Fatty acid composition of Liver Tissue in a variety of dietary conditions (a) CS (b) HCHF (c) CEPA (d) 
HEPA 
 
